{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-000684","form_type":"8-K","ticker":"SRTS","cik":"0001494891","company_name":"Sensus Healthcare, Inc.","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.717290+00:00","generated_at":"2026-06-27T20:34:14.618416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensus Healthcare expects record Q4 2021 sales over $25M, profitable Q4 and FY","bullets":["Expects record Q4 sales; full-year 2021 revenue over $25M.","Expects positive EBITDA and net income for Q4 and full year.","Q4 sales include three SRT systems shipped to China.","Also expects profitability for Q1 2022.","TransDermal Infusion System featured at Winter Clinical Dermatology Conference on Jan 15."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-000684","json":"https://secwatch.observer/filing/0001213900-22-000684.json","markdown":"https://secwatch.observer/filing/0001213900-22-000684.md","text":"https://secwatch.observer/filing/0001213900-22-000684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494891/000121390022000684/0001213900-22-000684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494891/000121390022000684/ea153545-8k_sensushealth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:34:14.618416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}